Both STAC2 and NELL1 promoter CpG island hypermethylation has been reported in metastatic breast cancer and primary colon cancer, respectively and GRP is implicated in the development of tumorigenicity and drug resistance. Here, NELL1 is linked to malignant colon neoplasm.